Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.
Bellanti JA, Lin FY, Chu C, Shiloach J, Leppla SH, Benavides GA, Karpas A, Moayeri M, Guo C, Robbins JB, Schneerson R.
Bellanti JA, et al.
Clin Vaccine Immunol. 2012 Feb;19(2):140-5. doi: 10.1128/CVI.05556-11. Epub 2011 Dec 21.
Clin Vaccine Immunol. 2012.
PMID: 22190398
Free PMC article.
Clinical Trial.
Volunteers were randomized to receive one of three formulations of rPA (formalin treated, alum adsorbed, or both), in 10- or 20-mug dosages each, or the licensed vaccine, AVA. ...Sera were collected before each injection and 1 week after the 1st, 2 weeks after the 3rd and …
Volunteers were randomized to receive one of three formulations of rPA (formalin treated, alum adsorbed, or both), in 10- or 20-mug d …